Pharmasynthesis R&D Center to be established in Skolkovo

It is planned to create an R&D Center and the headquarters of the Pharmasynthesis Group of companies, one of the largest Russian manufacturers of socially significant medicines, on the territory of the Skolkovo Innovation Center. The corresponding partnership agreement was signed by the Skolkovo Foundation (VEB Group.Russian Federation) and Pharmasynthesis.

The project provides for the creation of a multifunctional complex with an area of 15 thousand square meters. m. The facility will be located in the southern part of the Skolkovo Research Center, where a number of large corporate research centers are already operating. The construction of the complex is scheduled to begin at the end of 2026, completion by 2030, after which the R&D Center will be fully operational.

The establishment of the Pharmasynthesis research center in Skolkovo is a step towards creating a full cycle of pharmaceutical innovations — from an idea to a finished product, said Sergey Perov, Chairman of the Board of the Skolkovo Foundation. "We are creating an ecosystem in which the best Russian companies develop the medicine of the future. We are confident that the new R&D center will become a point of attraction for Russian and international partners in the field of healthcare and biotechnology," he said.

The involvement of Pharmasynthesis to locate the facility on the territory of the IC will help strengthen Russia's position in the global market of innovative medicines and pharmaceutical technologies, according to Skolkovo. This will help achieve the national goals of technological leadership within the framework of the national project "New technologies for saving health."

"We are creating a center in Skolkovo that will combine scientific developments, innovative technologies and management expertise of the group. This will accelerate the introduction of new medicines, increase the level of independence of the Russian pharmaceutical industry and strengthen the country's position in the global pharmaceutical innovation market," said Vikram Punia, Founder and President of Pharmasynthesis Group.

The Center will focus on the development and implementation of innovative medicines. It will combine auxiliary infrastructure — laboratories for conducting applied research, developing new dosage forms and preparing materials for clinical and preclinical trials.

According to Punia, Pharmasynthesis plans to use the resources of its own researchers and cooperate with institutes, universities and groups of scientists within the country. In addition, international intellectual and technological expertise, including its own and foreign institutions, will be actively involved. The center's activities also include the development of development processes and their effective management.

Pharmasynthesis Group of Companies is one of the leading Russian biopharmaceutical companies operating in various segments of the healthcare industry. The company develops and manufactures modern medicines for a wide range of medical fields, including oncology, hematology, endocrinology, as well as for the treatment of orphan, hormonal, infectious and other diseases. Pharmasynthesis drugs are used for the treatment of diabetes, tuberculosis, hepatitis, HIV infection, COVID-19, and chronic renal failure.